CONNECT WITH US
HealthTech

HealthTech

Post-Hoc Live: What the US midterm elections mean for biopharma

Endpoints News logo

Published on

Add as a preferred source on Google
Post-Hoc Live: What the US midterm elections mean for biopharma

🗳️ Live Wednesday at 1:30 pm ET! 🎙️ It’s Election Day in the US, and the results could have wide-ranging implications for biotech and pharma. Democratic control of Congress would mean new movement around drug pricing policy and scrutiny of the Trump administration’s “most favored nation” deals. It could mean investigations into HHS Secretary Robert F. Kennedy Jr., shifts in China policy, changes to funding rules for US research, plus more policy and people turbulence at the FDA. Tomorrow at 1:30 pm ET, Endpoints News Senior Reporter Max Bayer and I will be joined by frequent Post-Hoc Live guest Nick Shipley, an expert on biopharma policy and politics. We’ll break down what the midterms mean for biopharma and how the industry will navigate Washington over the next few years. Join us on YouTube (and set a Google or Outlook calendar alert for a reminder). See you after the votes, — Drew Armstrong, Executive Editor



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.